Literature DB >> 22770772

Evaluation of a commercial immunochromatographic assay for the serologic diagnosis of tularemia.

Selçuk Kiliç1, Bekir Celebi, Murat Yeşilyurt.   

Abstract

Tularemia is an infection caused by Francisella tularensis with a worldwide distribution in the northern hemisphere and diverse clinical manifestations. Serology plays an important role in the diagnosis of tularemia. A commercially available immunochromatographic assay (ICA) for the serologic diagnosis of tularemia (VIRapid Tularemia, Vircell, Granada, Spain) was evaluated, and the performance was compared with that of the current standard, the microagglutination test (MA). A panel of 221 sera from 109 cases of tularemia was tested as well as 236 sera from normal individuals or individuals with other infectious or autoimmune diseases. The ICA demonstrated 91.5% (κ = 0.91) agreement with the reference method (MA) and gave an overall sensitivity of 99.3% and a specificity of 94.6%. No cross-reactivity was observed in the ICA with serum samples from normal individuals and patients with autoimmune diseases and bacterial, viral, and parasitic infections, although 4 of 50 patients with brucellosis demonstrated positive results in the ICA. The performance of ICA was simple, and it requires no specialized equipment. The ease of use and significantly high sensitivity and specificity of ICA make it a good choice for diagnostic testing and a valuable field test to support a presumptive diagnosis of tularemia in remote areas.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22770772     DOI: 10.1016/j.diagmicrobio.2012.05.030

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  Usefulness of a single-assay chemiluminescence test (Tularaemia VIRCLIA IgG + IgM monotest) for the diagnosis of human tularemia. Comparison of five serological tests.

Authors:  África Cubero; Carlos Durántez; Ana Almaraz; Luis Fernández-Lago; María P Gutiérrez; María J Castro; Miguel A Bratos; María Simarro; Gabriel A March; Antonio Orduña
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-27       Impact factor: 3.267

2.  Evaluation of In-House and Commercial Serological Tests for Diagnosis of Human Tularemia.

Authors:  Hadjila Yanes; Aurélie Hennebique; Isabelle Pelloux; Sandrine Boisset; Dominique J Bicout; Yvan Caspar; Max Maurin
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948

3.  Performance of seven serological assays for diagnosing tularemia.

Authors:  Valérie Chaignat; Marina Djordjevic-Spasic; Anke Ruettger; Peter Otto; Diana Klimpel; Wolfgang Müller; Konrad Sachse; George Araj; Roland Diller; Herbert Tomaso
Journal:  BMC Infect Dis       Date:  2014-05-05       Impact factor: 3.090

4.  Tularemia in children, Turkey, September 2009-November 2012.

Authors:  Hasan Tezer; Aslınur Ozkaya-Parlakay; Hakan Aykan; Mustafa Erkocoglu; Belgin Gülhan; Ahmet Demir; Saliha Kanik-Yuksek; Anil Tapisiz; Meltem Polat; Soner Kara; Ilker Devrim; Selcuk Kilic
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

5.  Tularemia among free-ranging mice without infection of exposed humans, Switzerland, 2012.

Authors:  Francesco C Origgi; Barbara König; Anna K Lindholm; Désirée Mayor; Paola Pilo
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

6.  Pediatric Tularemia-A Case Series From a Single Center in Switzerland.

Authors:  Nina Schöbi; Philipp K A Agyeman; Andrea Duppenthaler; Andreas Bartenstein; Peter M Keller; Franziska Suter-Riniker; Kristina M Schmidt; Matthias V Kopp; Christoph Aebi
Journal:  Open Forum Infect Dis       Date:  2022-06-11       Impact factor: 4.423

7.  Rapid Identification and Characterization of Francisella by Molecular Biology and Other Techniques.

Authors:  Xin-He Lai; Long-Fei Zhao; Xiao-Ming Chen; Yi Ren
Journal:  Open Microbiol J       Date:  2016-04-14

Review 8.  Francisella tularensis, Tularemia and Serological Diagnosis.

Authors:  Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2020-10-26       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.